Drug intelligence / Profile preview

mdc-AH1

Development stage: Unknown
Lead developer: MedinCell
Modality: Small Molecules
Administration: Injectable

Overview

mdc-AH1 is a long-acting injectable veterinary product developed by MedinCell in partnership with Cornerstone Animal Health, utilizing MedinCell's proprietary BEPO technology. It was designed as a 5-7 day formulation for the treatment of acute pain in pets. The development program for mdc-AH1 was ultimately abandoned in December 2020 due to funding difficulties experienced by Cornerstone Animal Health, with the rights reverting to MedinCell.

Beyond the preview

Go deeper on mdc-AH1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mdc-AH1.

Explore the full profile